A Patient’s Guide To HIVEC™ Treatment
Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer Purpose To examine the effectiveness of hyperthermic intravesical chemotherapy (HIVEC™) with mitomycin-C (MMC) for patients with intermediate-high-risk non-muscle invasive bladder cancer (NMIBC).
HIVEC Treatment For Bladder Cancer | Fortis Cancer Institute
Introduction: There is increasing evidence that Hyperthermic Intravesical Chemotherapy is an effective treatment for non-muscle invasive bladder cancer (NMIBC). HIVEC (COMBAT BRS system) is an innovative hyperthermia delivering device. The aim of our study is to evaluate tolerance and safety of HIVEC in patients with BCG-refractory NMIBC.
Recirculant Hyperthermic IntraVEsical Chemotherapy …
Bladder Cancer Patients HIVEC. Bladder cancer is the 9th most common cancer worldwide, and the 5th most common in Europe*. Men are four times more likely to develop bladder cancer than women** however, this type of cancer often receives very little media attention.Bladder cancer is caused by an abnormal tissue growth, known as a tumour, which grows and spreads inside …
[Safety Of Hyperthermic IntraVEsical Chemotherapy …
Combat Bladder Recirculation System - HIVEC for the treatment of Bladder Cancer. BRS HIVEC® Treatment Animation “Combat’s HIVEC treatment is now our standard of care for NMIBC patients based on preliminary trial results showing similar efficacy to BCG but with a higher therapeutic adgerence.” Dr Felix Guerrero-Ramos, 12 Octubre Hospital, Madrid
Bladder Cancer Patients HIVEC - Hyperthermic Bladder …
02/03/2021 · Two of them experienced metastatic progression and died from bladder cancer. Conclusions: Chemohyperthermia using HIVEC device achieved a RFS rate of 60% at 1 year and enabled a bladder preservation rate of 92%. Given the low risk of progression in the N-BCG group, HIVEC could be a good alternative.
BRS HIVEC (Bladder Cancer) Technical Information - Combat Group
23/11/2021 · Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain. November 23, 2021 (1) Background: Intravesical mitomycin-C (MMC) combined with hyperthermia is increasingly used in non-muscle invasive bladder cancer (NMIBC), especially in the context of a relative BCG …
Efficacy Of Chemohyperthermia (HIVEC) In Patients With High-risk ...
Patient friendly information. Cancer Research UK website A trial of chemotherapy and hyperthermia for early bladder cancer (HIVEC II) Trial details. Chief Investigator: Prof J. Kelly. Trial contact: bci-hivec-ii@qmul.ac.uk. ISRCTN: 23639415. Sponsor: Queen Mary University of London. Participating countries: UK.
Long-Term Experience With Hyperthermic Chemotherapy (HIVEC) …
14/12/2019 · HIVEC is next big step to prevent recurrence in superficial bladder cancer Currently, bladder cancer in India is treated with Bacillus Calmette-Guerin (BCG) intravesical immunotherapy Topics